Johns Hopkins University spinout Blade Therapeutics has attracted $45m in commitments from investors including Pfizer, Novartis and Bristol-Myers Squibb.
US-based biopharmaceutical company Blade Therapeutics closed a $45m series B round yesterday led by Deerfield Management that featured pharmaceutical firms Pfizer, Novartis and Brisol-Myers Squibb.
Pfizer participated through its corporate venturing arm, Pfizer Venture Investments, while Novartis took part through its research division, Novartis Institutes of Biomedical Research.
Osage University Partners, a fund backed by a multitude of universities, and MPM Capital returned for the round after providing an undisclosed amount of funding that was reported as a $6.5m series…
